Abstract
Flavonoids are one of the most abundant secondary metabolites having a polyphenolic structure in plant and animal species with various desired pharmacological effects towards human health. Many flavonoid derivatives have been reported to possess neuroprotective activity through different mechanisms of action and, among them, cholinesterase (ChE) inhibition constitutes an important clinically applied treatment strategy of Alzheimer’s disease (AD). Some flavonoid derivatives have been demonstrated to inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to varying extent, which are called the sister enzymes linked to the pathogenesis of AD. On the other hand, diverse bioproduction techniques such as plant tissue culture, microbial transformation, etc. are applicable for flavonoids and, among them, production of flavonoids through metabolic engineering using special bacteria or yeast species has recently become popular. In the current review, some common flavonoids with ChE inhibitory effect as well as the examples of flavonoids obtained from metabolic engineering methods will be discussed.
Keywords: Alzheimer's disease, bioproduction, cholinesterase inhibition, flavonoid, metabolic engineering.
Current Pharmaceutical Biotechnology
Title:Implications of Some Selected Flavonoids Towards Alzheimer’s Disease with the Emphasis on Cholinesterase Inhibition and their Bioproduction by Metabolic Engineering
Volume: 15 Issue: 4
Author(s): Ilkay E. Orhan
Affiliation:
Keywords: Alzheimer's disease, bioproduction, cholinesterase inhibition, flavonoid, metabolic engineering.
Abstract: Flavonoids are one of the most abundant secondary metabolites having a polyphenolic structure in plant and animal species with various desired pharmacological effects towards human health. Many flavonoid derivatives have been reported to possess neuroprotective activity through different mechanisms of action and, among them, cholinesterase (ChE) inhibition constitutes an important clinically applied treatment strategy of Alzheimer’s disease (AD). Some flavonoid derivatives have been demonstrated to inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to varying extent, which are called the sister enzymes linked to the pathogenesis of AD. On the other hand, diverse bioproduction techniques such as plant tissue culture, microbial transformation, etc. are applicable for flavonoids and, among them, production of flavonoids through metabolic engineering using special bacteria or yeast species has recently become popular. In the current review, some common flavonoids with ChE inhibitory effect as well as the examples of flavonoids obtained from metabolic engineering methods will be discussed.
Export Options
About this article
Cite this article as:
Orhan E. Ilkay, Implications of Some Selected Flavonoids Towards Alzheimer’s Disease with the Emphasis on Cholinesterase Inhibition and their Bioproduction by Metabolic Engineering, Current Pharmaceutical Biotechnology 2014; 15 (4) . https://dx.doi.org/10.2174/1389201015666140813123204
DOI https://dx.doi.org/10.2174/1389201015666140813123204 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fibroblast Growth Factors in Development and Cancer: Insights from the Mammary and Prostate Glands
Current Drug Targets A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer
Current Pharmaceutical Analysis Antibodies in Diagnostic Applications
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Aptamers in Drug Design: An Emerging Weapon to Fight a Losing Battle
Current Drug Targets Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Expanding the Biotherapeutics Realm via miR-34a: “Potent Clever Little” Agent in Breast Cancer Therapy
Current Pharmaceutical Biotechnology Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Annona sp: Plants with Multiple Applications as Alternative Medicine - A Review
Current Bioactive Compounds Poly-L-arginine: Enhancing Cytotoxicity and Cellular Uptake of Doxorubicin and Necrotic Cell Death
Anti-Cancer Agents in Medicinal Chemistry Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Technologies for Translational Imaging Using Generators in Oncology
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenomics Opportunities in Nuclear Receptor Targeted Cancer Therapy
Current Cancer Drug Targets Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry A Potent Inhibitor of Steroid Sulfatase (EM-1913) Blocks Tumor Growth in Nude Mice (MCF-7 Xenograft)
Current Enzyme Inhibition Gene Therapy for Prostate Cancer: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging